Market Overview

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

Share:
Related ENDP
Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil
Watch Out Below, Endo International Investors, Management Is Doubling Down On Weak Assets

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.

In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”

Endo Health Solutions closed on Thursday at $35.96.

Latest Ratings for ENDP

DateFirmActionFromTo
Jan 2016BarclaysInitiates Coverage onEqual-weight
Nov 2015Mizuho SecuritiesDowngradesBuyNeutral
Nov 2015Standpoint ResearchUpgradesHoldBuy

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Corey Davis JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ENDP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters